Semalutide, he glucagon like peptide (GLP-1) receptor agonist, ua ʻae ʻia no ka mālama ʻana i ka maʻi diabetes type 2. Ua hoʻomohala ʻia ʻo Somaglutide e Novo Nordisk ma 2012 ma ke ʻano he koho lōʻihi i ka Liraglutide. Ke hoʻohālikelike ʻia me Liraglutide a me nā lāʻau maʻi diabetes ʻē aʻe, ʻo kekahi o nā mea maikaʻi o Somaglutide ʻo ia ka lōʻihi o ka hana ʻana, no laila ua lawa ka injection i hoʻokahi pule. I Kekemapa 2017, ua ʻae ka US Food and Drug Administration (FDA) i ke ʻano injection o somalutide. Ua ʻike ʻia kahi hoʻokolohua lapaʻau ma mua o ka pae II ua hoʻemi ʻo Somaglutide i ke kaumaha o nā maʻi maʻi diabetes type 2 a me nā poʻe momona, a ua manaʻo ʻia ke kaumaha o ke kaumaha ma muli o ka emi ʻana o ka ikehu ma muli o ka emi ʻana o ka makemake.